Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
暂无分享,去创建一个
Howard L. McLeod | Jamie K. Teer | H. McLeod | J. Teer | C. Walko | E. Padron | G. Bell | J. K. Hicks | Todd C. Knepper | N. Gillis | Eric Padron | Gillian C. Bell | J. Kevin Hicks | Teresa T. Vo | Nancy K. Gillis | Neil Thomas Mason | Christine M. Walko | T. Vo | T. Knepper | N. Mason
[1] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] F. Nicolantonio,et al. Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.
[3] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[4] David Fenstermacher,et al. Implementing personalized medicine in a cancer center. , 2011, Cancer journal.
[5] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[6] J. Simone. Understanding cancer centers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[8] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[9] M. Gilbert,et al. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Kurzrock,et al. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients , 2015, Molecular Cancer Therapeutics.
[11] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[12] Ariel Birnbaum,et al. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. , 2016, Journal of oncology practice.
[13] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[14] Douglas B. Johnson,et al. Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing. , 2017, Personalized medicine.
[15] R. D'Agostino,et al. Let's Not Put All Our Eggs in One Basket. , 2015, The New England journal of medicine.
[16] Suzanne Rose. Huge Data-Sharing Project Launched. , 2016, Cancer discovery.
[17] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[18] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[19] T. Hudson,et al. The Genetic Basis for Cancer Treatment Decisions , 2012, Cell.
[20] T. Hudson,et al. Unraveling the genetics of cancer: genome sequencing and beyond. , 2011, Annual review of genomics and human genetics.
[21] Theresa Zhang,et al. Personalized Genomic Analyses for Cancer Mutation Discovery and Interpretation. , 2015 .
[22] Gregory J Tsongalis,et al. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center. , 2015, The oncologist.
[23] J. Erdmann. All aboard: Will molecular tumor boards help cancer patients? , 2015, Nature Medicine.
[24] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[25] R. Schilsky,et al. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[27] S. Lippman,et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. , 2014, The oncologist.
[28] M. Robson,et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. , 2010, Journal of Clinical Oncology.